On May 12, 2021 Kureha Corporation reported that (Press release, Kureha Corporation, MAY 12, 2021, View Source [SID1234580129])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

I. FY2020 Results
Revenue growth driven by higher sales volumes in PVDF (LiB cathodes binder), agrochemicals, home products, fishing lines and environment businesses, partially offset by slower PPS (automobile components), PGA (shale oil and gas drilling tools), packaging materials, and industrial chemicals sales

• Core operating profit improved on higher revenue, coupled with lower fuel and raw materials cost and fewer SG&A expenses
• Operating profit declined primarily due to an impairment loss of ¥1.6bn related to the PGA business
• Profit before taxes decreased as a result of lower operating profit
• Profit attributable to the Company decreased as a result of lower profit before taxes Factors attributing to core operating profit (vs. FY2019)

AM: PGA-related operating loss (¥3bn) more than offsetting PVDF volume growth in the automobile LiB market SC: Higher agrochemicals volumes driven by improved demand and additional large-account sales offsetting declines in pharmaceuticals and industrial chemicals

SP: Robust volume growth in home products and fishing lines partially offset by lower packaging materials volumes
CO: Delays and cancellations of private construction projects offsetting steady public construction volumes
OO: Increased low-PCB waste treatment volumes and temporary volume growth related to post-typhoon wastes in the environment engineering business

On May 12, 2021 ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and GenScript Biotech Corporation (GenScript), the world’s leading research reagent provider, reported a non-exclusive license agreement granting GenScript access to ERS Genomics’ CRISPR/Cas9 patent portfolio (Press release, GenScript, MAY 12, 2021, https://www.genscript.com/ers-cenomics-and-genscript-biotech-corporation-sign-crispr-cas9-license-agreement.html [SID1234580068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GenScript is a global biotechnology company providing life sciences research and application products and services, with a presence in the USA, Asia-Pacific, and Europe. GenScript applies its proprietary oligonucleotide and gene synthesis technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. The ERS Genomics license will help further strengthen the GenScript CRISPR portfolio, from providing synthetic sgRNAs, gRNA plasmids, gRNA libraries, to cell line engineering services.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

On May 12, 2021 Novasep, a leading supplier of services and technologies for the life sciences industry, reported a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities on its Le Mans (72 – France) site (Press release, NOVASEP, MAY 12, 2021, View Source [SID1234580012]). This new step underlines customers’ confidence in Novasep’s expertise in HPAPIs & ADCs and reinforces Novasep’s position as a leading CDMO for the production of innovative and targeted molecules to treat cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This site, which has already benefitted from significant investment, continues to exhibit strong growth as a result of longstanding collaborations with major pharmaceutical companies & new partnerships with biotechnology innovators. To support this growth and sustain the increase in both clinical & commercial production capacity, Novasep is recruiting more than 30 people on this site, combined with an investment of more than €4 million.

Novasep has been a key partner to innovators in the ADC arena for more than 15 years. With a strong pipeline of customer’s clinical drug candidates leading to a number of recent ADC drug approvals, Novasep’s strategy of offering integrated development and manufacturing services for both payloads & bioconjugation is now bearing fruit. The state-of-the-art bioconjugation facility, launched in 2017 with an investment of €12 million, delivers cGMP ADC batches to customers and was successfully inspected by the ANSM (French regulatory drug authorities) in 2021. This demonstrates once again Novasep’s ability to offer flexible and reliable manufacturing solutions to oncology drug innovators, leveraging specialist technologies and expertise.

Dr. Michel Spagnol, Chairman and CEO of Novasep said "We are pleased to continue our development in strategic markets such as HPAPIs and ADCs, and to participate in the fight against cancer for the benefit of patients. Specifically, this expansion allows us to create more than 30 full-time jobs in Le Mans".

On May 12, 2021 Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, reported that Samira Sakhia, President and Chief Operating Officer, is scheduled to participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 8:35 am ET (Press release, Knight Therapeutics, MAY 12, 2021, View Source [SID1234579947]). A live webcast of the event will be available at the following link: Event. A copy of the presentation will be available at www.gud-knight.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 12, 2021 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, MAY 12, 2021, View Source [SID1234579946]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 RBC Capital Markets Global Healthcare – May 18-20, 2021

May 18, 2021, 11:30 a.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

UBS Global Healthcare Virtual Conference – May 24-26, 2021

May 26, 2021, 3:00 p.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

A copy of the presentation materials and/or webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.